[1] From “Nobel Lectures”, Chemistry 1942-1962, Elsevier Publishing Company,
[2] Carson, N.A.J.; Neill, D.W. Metabolic abnormalities detected in a survey of mentally
backward individuals in Northern Ireland. Arch Disease Child, 1962; 37: 505-513.
[3] McCully, K.S. Vascular pathology of homocysteinemia: implications for the
pathogenesis of arteriosclerosis. Am J Path, 1969; 56: 111-128.
[4] Pogribna, M.; Melnyk, S.; Pogribny, I.; Chango, A.; Yi, P.; James, S.J. Homocysteine
metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet,
[5] Ratnam, S.; Maclean, K.N.; Jacobs, R.L.; Brosnan, M.E.; Kraus, J.P.; Brosnan, J.T.
Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem,
[6] Pernod, G.; Bosson, J.L.; Golshayan, D.; Barro, C.; Forneris, G.; Martina, G.; Hurot,
J.M.; Turc-Baron, C.; Jouet, C.; Theytaz, J.; Jeantet, A.; Wauters, J.P.; Cordonnier, D.;
Diamant Alpin Collaborative Dialysis Study Group. Phenotypic and genotypic risk
Vitamin B Treatment and Cardiovascular Events in Hyperhomocysteinemic Patients 133
factors for cardiovascular events in an incident dialysis cohort. Kidney Int, 2006; 69:
[7] Smolders, R.G.; de Meer, K.; Kenemans, P.; Jakobs, C.; Kulik, W.; van der Mooren,
M.J. Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in
postmenopausal women but does not change the whole-body homocysteine
remethylation and transmethylation flux. J Clin Endocrinol Metab, 2005; 90: 2218-
[8] Van Guldener, C.; Janssen, M.J.F.M.; Stehouwer, C.D.A.; Jakobs, C.; Bronzwaer, J.G.;
Surachno, J.; Donker, A.J. The effects of renal transplantation on
hyperhomocysteinemia in dialysis patients, and the estimation of renal homocysteine
extraction in patients with normal renal function. Neth J Med, 1998; 52: 58-64.
[9] Guittormsen, A.B.; Ueland, P.M.; Svarstad, E.; Refsum, H. Kinetic basis of
hyperhomocysteinemia in patients with chronic renal failure. Kidney Int, 1997; 52: 495-
[10] Van Guldener C, Kulik W, Berger R, Dijkstra, D.A.; Jakobs, C.; Reijngoud, D.J.;
Donker, A.J.; Stehouwer, C.D.; De Meer, K. Homocysteine and methionine metabolism
in ESRD: a stable isotope study. Kidney Int, 1999; 56: 1064-1071.
[11] Czeizel, A.E. Folic acid in the prevention of neural tube defect. J Pediatr Gastroenterol
[12] Finkelstein, J.D. Methionine metabolism in mammals. J Nutr Biochem, 1990; 1: 228-
[13] Stam, F.; van Guldener, C.; ter Wee, P.M.; Jakobs, C.; de Meer, K.; Stehouwer, C.D.A.
Effect of folic acid on methionine and homocysteine metabolism in end-stage renal
disease. Kidney Int, 2005; 67: 259-264.
[14] Nedrebø, B.G.; Nygård, O.; Ueland, P.M.; Lien, E.A. Plasma total homocysteine in
hyper- and hypothyroid patients before and during 12 months of treatment. Clin Chem,
[15] Hussein, W.I.; Green, R.; Jacobsen, D.W.; Faiman, C. Normalization of
hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med, 1999;
[16] Matthews, D. Proteins and amino acids. In Modern Nutrition in Health and Disease,
Shils, M.; Olson, J.; Shike, M.; Ross, A., 9th Ed., Baltimore, Williams and Wilkins,
[17] Suliman, M.E.; Qureshi, A.R.; Barany, P.; Stenvinkel, P.; Filho, J.C.; Anderstam, B.;
Heimburger, O.; Lindholm, B.; Bergstrom, J. Hyperhomocysteinemia, nutritional
status, and cardiovascular disease in hemodialysis patients. Kidney Int, 2000; 57: 1727-
[18] Oishi, K.; Nagake, Y.; Yamasaki, H.; Fukuda, S.; Ichikawa, H.; Ota, K.; Makino, H.
The significance of serum homocysteine levels in diabetic patients on hemodialysis.
Nephrol Dial Transplant, 2000; 15: 851-855.
[19] Whittle, S.L.; Hughes, R.A. Folate supplementation and methotrexate treatment in
rheumatoid arthritis: a review. Rheumatology, 2004; 43: 267-271.
[20] Apeland, T.; Mansoor, M.A.; Strandpard, R.E. Antiepileptic drugs as independent
predictors of plasma total homocysteine levels. Epilepsy Res, 2001; 47: 27-35.
[21] Postuma, R.B.; Lang, A.E. Homocysteine and L-dopa: should Parkinson’s disease
patients receive preventative therapy? Neurology, 2004; 63: 886-891.
[22] Ubbink, J.B.; van der Merwe, A.; Delport, R.; Allen, R.H.; Stabler, S.P.; Riezler, R.;
Vermaak, W.J. The effect of a subnormal vitamin B-6 status on homocysteine
metabolism. J Clin Invest, 1996; 98: 177-184.
[23] Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with
folic acid based supplements: meta-analyses of randomised trials. BMJ, 1998; 316:
[24] Righetti, M.; Ferrario, G.M.; Milani, S.; Serbelloni, P.; La Rosa, L.; Uccellini, M.;
Sessa, A. Effects of folic acid treatment on homocysteine levels and vascular disease in
hemodialysis patients. Med Sci Monit, 2003; 9: PI 19-24.
[25] Sunder-Plassmann, G.; Födinger, M.; Buchmayer, H.; Papagiannopoulos, M.; Wojcik,
J.; Kletzmayr, J.; Enzenberger, B.; Janata, O.; Winkelmayer, W.C.; Paul, G.; Auinger,
M.; Barnas, U.; Hörl, W.H. Effect of high dose folic acid therapy on
Hyperhomocysteinemia in hemodialysis patients: results of the Vienna Multicenter
Study. J Am Soc Nephrol, 2000; 11: 1106-1116.
[26] Van Guldener, C.; Janssen, M.J.F.M.; Lambert, J.; ter Wee, P.M.; Jakobs, C.; Donker,
A.J.; Stehouwer, C.D. No change in impaired endothelial function after long-term folic
acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol Dial
Transplant, 1998; 13: 106-112.
[27] Ducloux, D.; Aboubakr, A.; Motte, G.; Toubin, G.; Fournier, V.; Chalopin, J.M.;
Drueke, T.; Massy, Z.A. Hyperhomocysteinemia therapy in hemodialysis patients:
folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial
Transplant, 2002; 17: 865-870.
[28] Righetti, M.; Tommasi, A.; Lagona, C.; La Rosa, L.; Uccellini, M.; Sessa, A. Effective
homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial
[29] Quinlivan, E.P.; McPartlin, J.; McNulty, H.; Ward, M.; Strani, J.J.; Weir, D.G.; Scott,
J.M. Importance of both folic acid and vitamin B12 in reduction of risk of vascular
disease. Lancet, 2002; 359: 227-228.
[30] Institute of Medicine. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin
B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington DC,
National Academy Press 2000; 150-195.
[31] Arnadottir, M.; Berg, A.L.; Hegbrant, J.; Hultberg, B. Influence of haemodialysis on
plasma total homocysteine concentration. Nephrol Dial Transplant, 1999; 14: 142-146.
[32] Arnadottir, M.; Wingren, K.; Hultberg, B.; Hegbrant, J. The postdialytic rise in the
plasma total homocysteine concentration is delayed. Blood Purif, 2002; 20: 334-337.
[33] House, A.A.; Wells, G.A.; Donnelly, J.G.; Nadler, S.P.; Hèbert, P.C. Randomized trial
of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol
Dial Transplant, 2000; 15: 1029-1034.
[34] Mudge, D.W.; Rogers, R.; Hollett, P.; Law, B.; Reiger, K.; Petrie, J.J.B.; Price, L.;
Johnson, D.W.; Campbell, S.B.; Isbel, N.M.; Sullivan, M.; Hawley, C.M. Randomized
trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrol
Dial Transplant, 2005; 20: 2178-2185.
Vitamin B Treatment and Cardiovascular Events in Hyperhomocysteinemic Patients 135
[35] Van Telligen, A.; Grooteman, M.P.; Bartels, P.C.; Van Limbeek, J.; Van Guldener, C.;
[36] De Vriese, A.S.; Langlois, M.; Bernard, D.; Geerolf, I.; Stevens, L.; Boelaert, J.R.;
Schurgers, M.; Matthys, E. Effect of dialyser membrane pore size on plasma
homocysteine levels in hemodialysis patients. Nephrol Dial Transplant, 2003; 18:
[37] Galli, F.; Benedetti, S.; Buoncristiani, U.; Piroddi, M.; Conte, C.; Canestrai, F.;
Buoncristiani, E.; Floridi, A. The effect of PMMA-based protein-leaking dialyzers on
plasma homocysteine levels. Kidney Int, 2003; 64: 748-755.
[38] Righetti, M.; Ferrario, G.M.; Serbelloni, P.; Milani, M.; Tommasi, A. Nephrol. Dial.
Transplant., 2006; 21: 2034-2035.
[39] Beerenhout, C.; Luik, A.J.; Jeuken-Mertens, S.G.J.; Bekers, O.; Menheere, P.; Hover,
L.; Klaassen, L.; van der Sande, F.M.; Cheriex, E.C.; Meert, N.; Leunissen, K.M.;
Kooman, J.P. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a
randomised prospective study. Nephrol. Dial. Transplant., 2005; 20: 1155-1163.
[40] Friedman, A.N.; Bostom, A.G.; Levy, A.S.; Rosenberg, I.H.; Selhub, J.; Pierratos, A.
Plasma total homocysteine levels among patients undergoing nocturnal vs standard
hemodialysis. J. Am. Soc. Nephrol., 2002; 13: 265-268.
[41] Moustapha, A.; Gupta, A.; Robinson, K.; Arheart, K.; Jacobsen, D.W.; Schreiber, M.J.;
Dennis, V.W. Prevalence and determinants of hyperhomocysteinemia in hemodialysis
and peritoneal dialysis. Kidney Int., 1999; 55: 1470-1475.
[42] Johnson, D.W.; Kay, T.D.; Vesey, D.A.; Isbel, N.; Campbell, S.B.; Hawley, C.M.
Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit.
[43] Scholze, A.; Rinder, C.; Beige, J.; Riezler, R.; Zidek, W.; Tepel, M. Acetylcysteine
reduces plasma homocysteine concentration and improves pulse pressure and
endothelial function in patients with end-stage renal failure. Circulation, 2004; 109:
[44] Thaha, M.; Yogiantoro, M.; Tomino, Y. Intravenous N-acetylcysteine during
controlled study. Am J Kidney Dis, 2003; 41: 442-446
[46] Tepel, M.; van der Giet, M.; Statz, M.; Jankowski, J.; Zidek, W. The antioxidant
acetylcysteine reduces cardiovascular events in patients with end-stage renal failure.
Circulation, 2003; 107: 992-995
[47] Urquhart BL, Freeman DJ, Spence JD, House AA. The effect of mesna on plasma total
homocysteine concentration in hemodialysis patients. Am J Kidney Dis, 2007; 49: 109-
[48] Perna, A.F.; Ingrosso, D.; Lombardi, C.; Acanfora, F.; Satta, E.; Cesare, C.M.; Violetti,
E.; Romano, M.M.; De Santo, N.G. Possibile mechanisms of homocysteine toxicity.
Kidney Int, 2003; 63: S137-S140.
[49] Hubmacher, D.; Tiedemann, K.; Bartels, R.; Brinckmann, J.; Vollbrandt, T.; Bätge, B.;
Notbohm, H.; Reinhardt, D.P. Modification of the structure and function of fibrillin-1
by homocysteine suggests a potential pathogenetic mechanism in homocystinuria. J.
Biol. Chem., 2005; 280: 34946-34955.
[50] Ingrosso, D.; Cimmino, A.; Perna, A.F.; Masella, L.; De Santo, N.G.; De Bonis, M.L.;
Vacca, M.; D’Esposito, M.; D’Urso, M.; Galletti, P.; Zappia, V. Folate treatment and
unbalanced methylation and changes of allelic expression induced by
hyperhomocysteinemia in patients with uremia. Lancet, 2003; 361: 1693-1699.
[51] Baigent, C.; Burbury, K.; Wheeler, D. Premature cardiovascular disease in chronic
renal failure. Lancet, 2000; 356: 147–152.
[52] Eknoyan, G.; Lameire, N.; Barsoum, R.; Eckardt, K.U.; Levin, A.; Levin, N.; Locatelli,
F.; MacLeod, A.; Vanholder, R.; Walker, R.; Wang, H. The burden of kidney disease:
improving global outcomes. Kidney Int, 2004; 66: 1310–1314.
[53] Rayner, H.C.; Pisoni, R.L.; Bommer, J.; Canaud, B.; Hecking, E.; Locatelli, F.; Piera,
L.; Bragg-Gresham, J.L.; Feldman, H.I.; Goodkin, D.A.; Gillespie, B.; Wolfe, R.A.;
Held, P.J.; Port, F.K. Mortality and hospitalization in haemodialysis patients in five
European countries: results from the Dialysis Outcomes and Practice Patterns Study
(DOPPS). Nephrol Dial Transplant, 2004; 19: 108–120
[54] Conte, F.; Salomone, M. Italian Registry of Dialysis and Transplantation, Report 2001.
Available from: http://www.sin-ridt.org/sin-ridt/sin-ridt.org.htm
[55] Graham, I.M.; Daly, L.E.; Refsum, H.M.; Robinson, K.; Brattstrom, L.E.; Ueland,
P.M.; Palma-Reis, R.J.; Boers, G.H. Plasma homocysteine as a risk factor for vascular
disease. The European Concerted Action Project. J Am Med Assoc, 1997; 277: 1775-
[56] Wald, D.S.; Law, M.; Morris, J.K. Homocysteine and cardiovascular disease: evidence
on causality from a meta-analysis. Br Med J, 2002; 325: 1202-1208.
[57] Fissell, R.B.; Bragg-Gresham, J.L.; Gillespie, B.W.; Goodkin, D.A.; Bommer, J.; Saito,
A.; Akiba, T.; Port, F.K.; Young, E.W. International variation in vitamin prescription
and association with mortality in the Dialysis Outcomes and Practice Patterns Stuudy
(DOPPS). Am J Kidney Dis, 2004; 44: 293-299.
[58] Righetti, M.; Serbelloni, P.; Milani, S.; Ferrario, G.M. Homocysteine-lowering vitamin
B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif.,
[59] Kalantar-Zadeh, K.; Block, G.; Humphreys, M.H.; Mcallister, C.J.; Kopple, J.D. A low,
rather than a high, total plasma homocysteine is an indicator of poor outcome in
hemodialysis patients. J Am Soc Nephrol, 2004; 15: 442-453.
[60] Wrone, E.M.; Hornberger, J.M.; Zehnder, J.L.; Mccann, L.M.; Coplon, N.S.; Fortmann,
S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage
renal disease. J Am Soc Nephrol, 2004; 15: 420–426.
[61] Ducloux, D.; Klein, A.; Kazory, A.; Devillard, N.; Chalopin, J.M. Impact of
malnutrition-inflammation on the association between homocysteine and mortality.
Kidney Int., 2006; 69: 331-335.
[62] Suliman, M.; Stenvinkel, P.; Qureshi, A.R.; Kalantar-Zadeh, K.; Barany, P.;
Heimbürger, O.; Vonesh, E.F.; Lindholm, B. The reverse epidemiology of plasma total
Vitamin B Treatment and Cardiovascular Events in Hyperhomocysteinemic Patients 137
homocysteine as a mortality risk factor is related to the impact of wasting and
inflammation. Nephrol Dial Transplant, 2007; 22: 209-217
[63] Yap, S.; Boers, G.H.J.; Wilcken, B.; Wilcken, D.E.L.; Brenton, D.P.; Lee, P.J.; Walter,
J.H.; Howard, P.M.; Naughten, E.R. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 2080-
[64] Yang, Q.; Botto, L.D.; Erickson, J.D.; Berry, R.J.; Sambell, C.; Johansen, H.;
Friedman, J.M. Improvement in stroke mortality in Canada and the United States, 1990
to 2002. Circulation, 2006; 13: 1335-1343
[65] Bazzano, LA; Reynolds, K; Holder, KN; He, Y. Effect of folic acid supplementation on
risk of cardiovascular diseases. JAMA, 2006 ; 296: 2720-2726
Comments
Post a Comment
اكتب تعليق حول الموضوع